- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03077295
The Big Breakfast Study
Role of Breakfast Size and Composition for Appetite Control and Energy Balance
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The aim of this study is to further strengthen our understanding of the role of dietary components (in particular fibre and protein) in a healthy diet. The information gained from this research will lead to better policy advice, particularly in relation to healthy weight management, metabolic control, mental health and intestinal health. It will also lay the foundations to produce healthier primary products and aid the food industry in developing new and healthier products (e.g. products that aid hunger control and satiety). This will be addressed through four interlinked objectives:
O1: Healthy weight management and improved metabolic and mental health O2: Identification of gut bacteria and compounds of relevance to vascular and gut health O3: Linking fibre consumption to intestinal microbial communities and health O4: Mathematical modelling of interactions between diet and gut microbial communities
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Aberdeen, Verenigd Koninkrijk, AB25 2ZD
- The Rowett Institute
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- BMI ranging from 27-42 kg/m2;
- those habitually consuming breakfast (at least 5 times a week).
Exclusion Criteria:
- women who are pregnant, planning to be pregnant or breastfeeding
- subjects with food allergy
- diagnosis of diabetes, hypertension, renal, hepatic, haematological disease or coronary heart disease
- having given a pint of blood for transfusion purposes within the last month
- unsuitable veins for blood sampling
- inability to understand the participant information sheet
- inability to speak, read and understand the English language
- those on any prescription medications (other than oral contraceptives)
- those on any specific diet regimes
- those on any weight loss programmes (that may be affecting lifestyle, physical activity and diet).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: High Fibre to High-Protein (HF-HP)
|
High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch.
Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g.
wheat bran, fava bean, lentil, buckwheat).
Andere namen:
• High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch.
Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy.
Total dietary fibre will be no more than 15g/d for 2000kcal intake.
Andere namen:
|
|
Experimenteel: High Protein to High-Fibre (HP-HF)
|
High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch.
Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g.
wheat bran, fava bean, lentil, buckwheat).
Andere namen:
• High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch.
Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy.
Total dietary fibre will be no more than 15g/d for 2000kcal intake.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Energy Balance
Tijdsspanne: measured up to day 71 of study
|
Chronic influence on energy balance (body weight, kg)
|
measured up to day 71 of study
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Acute effects on appetite after test meals
Tijdsspanne: Baseline & week 4 of each treatment
|
Appetite questionnaires recorded on Visual Analogue Scales every 30mins on test days
|
Baseline & week 4 of each treatment
|
|
Acute effects on biomarkers of health after test meals
Tijdsspanne: Baseline & week 4 of each treatment
|
blood samples analysed for Glucose, Lipids and Hormones
|
Baseline & week 4 of each treatment
|
|
Acute effects on gastric emptying after test meals
Tijdsspanne: Baseline & week 4 of each treatment
|
gastric emptying (stable isotope, Octanoic acid labelled breath samples)
|
Baseline & week 4 of each treatment
|
|
Resting Metabolic Rate (RMR) before & after test meals
Tijdsspanne: Baseline & week 4 of each treatment
|
Chronic influence on metabolism or Thermic Effect of Food (TEF) using indirect calorimetry measurement
|
Baseline & week 4 of each treatment
|
|
Faecal sample analysis for gut health
Tijdsspanne: up to 10 weeks
|
Chronic influence on changes in gut microbiota
|
up to 10 weeks
|
|
Bone Density
Tijdsspanne: Baseline & week 4 of each treatment
|
Dual Energy X-ray Absorptiometry (DXA) Scan to measure fat mass, fat free mass & bone density as part of the 4 compartment model
|
Baseline & week 4 of each treatment
|
|
Body Composition
Tijdsspanne: Baseline & week 4 of each treatment
|
Air Displacement Plethysmography (BodPod) to measure body fat as part of the 4 compartment model
|
Baseline & week 4 of each treatment
|
|
Total Body Water
Tijdsspanne: Baseline & week 4 of each treatment
|
Deuterium Dilution to measure Total Body Water (TBW) as part of the 4 compartment model
|
Baseline & week 4 of each treatment
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Alexandra Johnstone, PhD, Senior Research Fellow
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 804
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .